NCT00742131 - A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally to Subjects With Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 17, 2005

Primary Completion Date

May 13, 2008

Study Completion Date

August 29, 2011

Conditions

Solid Tumours

Interventions

DRUG

GSK1363089

GSK1363089 will be administered orally as a cinnamon-flavored liquid (250 milligrams of GSK1363089 in 50 milliliters liquid \[5 milligrams/milliliter\] or 1000 milligrams of GSK1363089 in 50 milliliters liquid \[20 milligrams/milliliter\]) or as solid capsules of 20, 100, and/or 200 milligrams.